Thiazides, potassium citrate improve health-related QOL of patients with urolithiasis
Use of potassium citrate and thiazides appears to improve health-related quality of life (HRQOL) among stone formers across all Wisconsin Stone Quality of Life (WISQOL) domains without increasing the likelihood of gastrointestinal complaints and fatigue or sexual complaints, respectively, reports a study.
“These findings may be useful when counseling patients regarding the initiation of potassium citrate or thiazides for medical management of nephrolithiasis,” the authors said.
A total of 1,511 patients (787 males) were included in the study, of which 279 were on potassium citrate and 238 on thiazides. HRQOL in each domain was higher among patients treated with potassium citrate compared to those not treated with the said therapy (p<0.001). HRQOL was also higher among patients who received thiazides vs those who did not receive the said medication (p<0.01 for all).
Nausea, stomach upset or cramps (odds ratio [OR], 0.57; p<0.001) were less commonly reported among patients prescribed potassium citrate vs those not prescribed the said therapy. Moreover, patients who received thiazides were less likely to report fatigue (OR, 0.63; p=0.004) or reduced sexual interest and/or activity (OR, 0.64; p=0.005) compared to those who did not take the said treatment.
The authors obtained cross-sectional data on stone-forming enrolees in the North America Stone Quality of Life Consortium. They compared HRQOL between patients treated and not treated with potassium citrate or thiazide-type diuretics using the WISQOL questionnaire.
In addition, the authors compared the likelihood of gastrointestinal complaints between patients prescribed and not prescribed potassium citrate, as well as the likelihood of fatigue and sexual complaints in those prescribed and not prescribed thiazides.